Antiretroviral resistance testing in HIV patients
Pichon Riviere A, Augustovski F, Regueiro A, Garcia Marti S, Glujovsky D
Record ID 32005000642
Spanish
Authors' objectives:
The aim of this report is to evaluate the diagnostic-therapeutic usefulness of antiretroviral resistance testing and its implications in the clinical practice.
Authors' results and conclusions:
Prospective clinical trials have demonstrated a significant, although modest improvement, in the virologic results using genotype testing; and some, but not all trials with phenotyping could demonstrate an improvement in therapeutic results. The main results are seen mainly in markers such as viral load. There are no long-term results on survival. In clinical trials, a 0.5 log mean reduction has been observed in the viral load at 12-24 weeks, after a treatment change based on resistance testing in patients who had already received treatment.
Authors' recommendations:
The HIV-1 genotype and phenotype resistance testing are part of the diagnostic-therapeutic tools currently available for the management of HIV patients. They are used to determine therapeutic alternatives after treatment failure for patients previously treated with highly active antiretroviral therapy (HAART) or in special cases for patients recently infected who meet selection criteria (pregnant women infected with HIV of unknown source in areas of resistant HIV strains; patients without antiretroviral treatment infected from HIV positive patients with known therapeutic drug failure).Drug failure is defined as any viral load detected in two occasions, measured at least two weeks apart, in patients with previously undetected viral loads; or an increase of 0.5 log in the viral load of patients who have never had undetectable viral load.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.iecs.org.ar/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Drug Resistance, Viral
- Treatment Failure
- Anti-HIV Agents
- HIV Infections
- Reverse Transcriptase Inhibitors
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.